BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• Press Releases

  VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data

  August 26, 2026

   · 

  4 min read
• Press Releases

  HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure

  August 26, 2026

   · 

  4 min read
• Press Releases

  SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’

  August 26, 2026

   · 

  15 min read
• 

  FDA

  FDA eyes 2 new deputy commissioner posts: Report

  Though the potential change is unconfirmed, media outlets reported Wednesday that one deputy commissioner would focus on the intersection between health and AI, while another will be dedicated to drugs.

  August 26, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Cronus Pharma Launches First FDA-Approved Bioequivalent Robenacoxib Injection for Veterinary Use - August 26, 2026

  August 26, 2026

   · 

  2 min read
• 

  Approvals

  Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera

  Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.

  August 26, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Biohaven could get up to $795M in epilepsy alliance with SK Bio

  At the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.

  August 26, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026

  August 26, 2026

   · 

  18 min read
• Press Releases

  Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

  August 26, 2026

   · 

  4 min read
• Press Releases

  Ligand to Participate in September 2026 Investor Conferences

  August 26, 2026

   · 

  1 min read